NyokAssist™ pVAD Featured in Multiple Challenging Cases on Day One of TCT 2025

On the first day of TCT 2025, held in San Francisco, multiple clinical cases presented on October 25 highlighted the use of the NyokAssist™  Percutaneous Ventricular Assist Device (pVAD) in high-risk PCI and advanced heart failure management.

During the Challenging Case – Hemodynamic Instability: Novel MCS session, six clinical presentations highlighted how temporary mechanical circulatory support can facilitate complex coronary interventions and enhance procedural safety in patients with severely impaired cardiac function.

Case topics included

• Complete Revascularization in Patients with Two CTOs and Low Ejection Fraction

Dr. Xiu, Nanfang Hospital, Southern Medical University

 — Successful dual CTO-PCI in a patient with LVEF 24%, achieving full revascularization and stable hemodynamics.

• Staged CHIP-PCI with a Novel Left Ventricular Assist Device

Dr. Zhaowei Zhu, The Second Xiangya Hospital of Central South University

 — Staged revascularization in ischemic cardiomyopathy and PAD, supported throughout with stable flow and uneventful recovery.

• Successful PCI for Two CTOs in Severe LV Dysfunction and Anomalous RCA Origin

Xiamen Cardiovascular Hospital, Xiamen University

 — Safe completion of dual CTO-PCI under continuous hemodynamic support.

• A Novel pVAD Support for Complex High-Risk PCI

Dr. Jun Jiang, The Second Affiliated Hospital, Zhejiang University School of Medicine

 — The NyokAssist™ Percutaneous VAD was used to maintain hemodynamic stability throughout the prolonged intervention, enabling safe and complete revascularization.

• Advanced Heart Failure with Multivessel Coronary Artery Disease Managed by pVAD Support

The First Hospital of Lanzhou University

 — pVAD-assisted PCI achieved complete revascularization in a patient with EF 20%, maintaining stability and enabling recovery.

• Complete Revascularization for Diffused Severe Calcified Triple-Vessel Disease Supported with pMCS

Dr. Tao Chen, The First Affiliated Hospital of Xi'an Jiaotong University

 — Full revascularization achieved in triple-vessel, heavily calcified disease, with rapid recovery and improved cardiac function on follow-up.

These real-world cases reflect the increasing clinical adoption of temporary percutaneous ventricular support as an important adjunct in complex and high-risk PCI. The presentations drew strong interest from the audience, who engaged in active discussions on device performance, flow settings, stability in large ventricles, and extended support duration. The interaction underscored clinicians'growing confidence in this novel percutaneous VAD and its role in advancing high-risk PCI practice.

NyokAssist™ has been granted the Breakthrough Device Designation by U.S. FDA and Innovative Medical Device by the Chinese National Medical Products Administration (NMPA). 

Key design strengths of the NyokAssist™  pVAD include:

• Foldable and 9 Fr-compatible access, allowing less invasive insertion and broader clinical applicability.

• Strong flow support up to 5 L/min, providing sufficient hemodynamic assistance during complex procedures.

• Enhanced procedural safety, minimizing hemodynamic instability in patients with severe LV dysfunction.

• Simplified setup and retrieval, streamlining workflow for interventional teams.

As TCT continues to serve as a leading global platform for interventional cardiology, the presence of NyokAssist™  across multiple presentations underscores magAssist's commitment to advancing mechanical circulatory support and enabling physicians with innovative tools that improve outcomes for patients with complex cardiac conditions.

About TCT

Founded by Dr. Martin B. Leon, the Transcatheter Cardiovascular Therapeutics®) (TCT® conference is the annual scientific symposium of the Cardiovascular Research Foundation® (CRF®)) and the world's foremost educational forum specializing in interventional cardiovascular medicine.

Debuting as a small gathering of 150 in 1988, TCT® now attracts thousands of attendees from around the world. Every year, TCT® features major medical research breakthroughs and gathers leading researchers and clinicians from around the world to present and discuss the latest evidence-based research.